Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional F9 gene to patients with hemophilia B. It enables the liver to produce factor IX (FIX) endogenously, potentially eliminating the need for routine factor replacement prophylaxis.
## Primary Indications
Treatment of adults with moderately severe to severe hemophilia B (congenital factor IX deficiency) who are currently using factor IX prophylactic therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is 5 x 10^11 vector genomes per kilogram (vg/kg) of body weight, administered as a single-dose intravenous infusion.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients. Use in patients under 18 years of age is not currently indicated.
## Dose Adjustments
There are no dose modifications for hepatic or renal impairment; however, patients must have stable liver function tests prior to administration. The dose is fixed based on weight and is not adjusted post-administration.
## Contraindications
* Hypersensitivity to the active substance or any excipient.
* Active, uncontrolled infections (acute or chronic).
* Advanced hepatic fibrosis or cirrhosis.
## Adverse Effects
* **Common:** Elevated liver enzymes (transaminases), which may necessitate corticosteroid intervention to prevent loss of transgene expression.
* **Other:** Infusion-related reactions (headache, nausea, fever, tachycardia, hypotension), fatigue, and elevated creatine kinase.
## Key Drug Interactions
* **Corticosteroids:** Often required following administration to manage immune-mediated hepatotoxicity.
* **Immunomodulators:** Concurrent use of other immunosuppressants should be monitored closely as they may influence the durability of the vector expression.
* **Hepatotoxic Agents:** Avoid or limit use of other potential hepatotoxins while monitoring post-infusion liver enzymes.
## Monitoring
* **Liver Enzymes:** Monitor ALT/AST levels at least weekly for at least 3 months post-infusion to detect immune-mediated hepatotoxicity.
* **Factor IX Activity:** Regular monitoring of FIX activity levels to assess sustained therapeutic expression.
* **Bleeding Events:** Continuous monitoring for breakthrough bleeding.
## Clinical Pearls
* **Prophylaxis Transition:** Patients may continue factor IX prophylaxis for a short period after infusion until FIX levels rise to a therapeutic range.
* **AAV Antibodies:** Pre-screening for anti-AAV antibodies is mandatory; patients with pre-existing antibodies may not be eligible for treatment as these may neutralize the therapeutic vector.
* **Steroid Taper:** If ALT elevation occurs, clinicians must initiate a corticosteroid taper (e.g., prednisone 60 mg/day). Ensure patient adherence to this taper to protect the transgene.
* **Efficacy:** The clinical goal is achieving sustained endogenous FIX production; monitor for long-term durability.
***
**Educational Disclaimer:** This summary is for informational purposes for healthcare professionals. Dosing and clinical protocols may vary based on local institutional guidelines, patient-specific factors, and updated regulatory guidance. Always consult the most current FDA-approved prescribing information (package insert) and institutional pharmacy protocols before prescribing or administering gene therapy products.
